Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there ...

New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

THERE’S been an “alarming” increase in HIV infections among straight women, a new report warns. It comes as sexual health ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

China has announced a US$3.49 million (R60 million) partnership with South Africa to expand HIV prevention services among adolescents and young people, as ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after ...